Application of Green Tea Catechin for Inducing the Osteogenic Differentiation of Human Dedifferentiated Fat Cells in Vitro.
Application of Green Tea Catechin for Inducing the Osteogenic Differentiation of Human Dedifferentiated Fat Cells in Vitro.
复制标题
DOI：
10.3390/ijms161226081
复制
发表时间：
2015-11-25
影响因子：
5.6
通讯作者：
Baba S
中科院分区：
文献类型：
--
作者：
Kaida K;Honda Y;Hashimoto Y;Tanaka M;Baba S
尽管干细胞生物学取得了进展，但很少有有效的技术来促进人类原发去分化脂肪细胞(DFAT)的成骨分化。我们试图研究绿茶儿茶素的主要成分表没食子儿茶素没食子酸酯(EGCG)是否能促进体外培养的DFAT细胞的早期成骨分化和矿化。DFAT细胞在含或不含地塞米松(DEX)的成骨培养液(OM)中加入EGCG1.2 5~10μM，共培养12天。在这两种培养上清液中加入1.25μM-EGCG，均能有效地增加细胞中胶原1(COL1A1)和矮小相关转录因子2(RUNX2)的基因表达，并促进细胞增殖和矿化。与含EGCG的OM(Dex)相比，含EGCG的OM(Dex)在第1天诱导COL1A1和RUNX2的表达较早，在第12天时矿化水平较高。OM(Dex)+10μM EGCG明显抑制DFAT细胞的增殖。这些结果提示OM(不含地塞米松)加EGCG可能是促进DFAT细胞增殖和诱导成骨细胞分化的一种较好的培养液。我们的发现为联合使用EGCG和DFAT细胞进行骨再生和基于干细胞的治疗提供了洞察力。
Despite advances in stem cell biology, there are few effective techniques to promote the osteogenic differentiation of human primary dedifferentiated fat (DFAT) cells. We attempted to investigate whether epigallocatechin-3-gallate (EGCG), the main component of green tea catechin, facilitates early osteogenic differentiation and mineralization on DFAT cells in vitro. DFAT cells were treated with EGCG (1.25–10 μM) in osteogenic medium (OM) with or without 100 nM dexamethasone (Dex) for 12 days (hereafter two osteogenic media were designated as OM(Dex) and OM). Supplementation of 1.25 μM EGCG to both the media effectively increased the mRNA expression of collagen 1 (COL1A1) and runt-related transcription factor 2 (RUNX2) and also increased proliferation and mineralization. Compared to OM(Dex) with EGCG, OM with EGCG induced earlier expression for COL1A1 and RUNX2 at day 1 and higher mineralization level at day 12. OM(Dex) with 10 μM EGCG remarkably hampered the proliferation of the DFAT cells. These results suggest that OM(without Dex) with EGCG might be a preferable medium to promote proliferation and to induce osteoblast differentiation of DFAT cells. Our findings provide an insight for the combinatory use of EGCG and DFAT cells for bone regeneration and stem cell-based therapy.